Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / proPSA



This biomarker is also known as:
  • [-2]proPSA,
  • free prostate-specific antigen (PSA) isoform,

View in BioMuta


ProPSA (-2), or [-2]proPSA, is a PSA isoform which has a leader peptide (-2) amino acids at its N terminal region and does not interact with ACT or alpha-2-macroglobulin or spermidine and therefore is detected as a separate isoform. ProPSA is produced primarily in the peripheral zone of the prostate gland and therefore is very useful in distinguishing between prostate cancer patients with PSA range of 2-10, from those who have BPH. Percent proPSA is the ratio of proPSA to free PSA. In July 2012 the FDA approved an assay measuring levels of [-2]proPSA for monitoring and diagnostic purposes.


QA State: Curated
Type: Protein
Short Name:
HGNC Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Three
QA State: Curated


The measurement of PSA, free PSA, and pro-PSA can help a patient determine whether to undergo biopsy if his PSA level is between 4 and 10 ng/mL.

Performance Comment

In July 2012 the FDA approved an assay measuring levels of [-2]proPSA, a form of pro-PSA, for monitoring and diagnostic purposes.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

2015 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place January 20–21, 2016 in Bethesda, Maryland.

Announcement 08/26/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Wednesday-Thursday, January 20-21, 2016, on the NCI campus. More information will be available later this summer.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to /grants/guide/ pa-files/ PAR-15-289.html.